In IPF fibroblasts, we found nintedanib treatment was associated with upregulation of hsa-miR-486-3p, which might repress DDX11, E2F1, and PLXNA4 expressions. This evidence concerns the gene PLXNA4 and idiopathic pulmonary fibrosis.